Swiss pharmaceutical giant, Roche, on Monday presented new data on its phase three trial of an antibody cocktail.
The antibody cocktail is meant to reduce the risk of a symptomatic case of COVID-19, the company said in a statement.
The Basel-headquartered company said that its latest data set showed that the subcutaneous administration of a cocktail of casirivimab and imdevimab reduced the risk of a symptomatic case by 81 per cent.
“Among individuals, who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration,’’ it stated.
The company added that a in group of recently infected asymptomatic patients, the cocktail reduced the risk of progressing to symptomatic COVID-19 by 31 per cent.
The data would be shared with regulatory authorities in Europe and the United States, the company said.
